Role of gut microbiota and tryptophan metabolism in nonalcoholic fatty liver disease

Qingling ZHONG; Liangping LI

doi:10.3969/j.issn.1001-5256.2022.06.040

Volume 38 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(6): 1411-1415

PDF( 2304 KB)

Role of gut microbiota and tryptophan metabolism in nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.06.040

Qingling ZHONG^{1, 2},
Liangping LI^{2
,
,
,}

1.
School of Medicine, University of Electronic Science and Technology of China, Chengdu 610054, China
2.
Department of Gastroenterology, Sichuan Provincial People's Hospital & The Affiliated Hospital of University of Electronic Science and Technology of China, Chengdu 610072, China

More Information

Corresponding author: LI Liangping, 18981838872@163.com (ORCID: 0000-0004-1808-0950)
Received Date: 2021-10-09
Accepted Date: 2021-11-12
Published Date: 2022-06-20

Abstract

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a manifestation of multi-system dysfunction involving the liver, ranging from simple hepatic steatosis to nonalcoholic steatohepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. An increasing number of studies have shown the importance of the changes in gut microbiota dysbiosis and its metabolites in NAFLD. Tryptophan and its derivatives produced by gut microbiota have the effects on improving intestinal barrier function, regulating abnormal glucose and lipid metabolism, and alleviating insulin resistance and inflammatory response. This article reviews gut microbiota, tryptophan and its metabolites, and the effect of their interaction on NAFLD.
- Non-alcoholic Fatty Liver Disease,
- Gastrointestinal Microbiome,
- Tryptophan

FullText(HTML)

References(51)

References

[1]	LIU QH, ZHAO Y, HU YY. Effect of diet on enterotype-related gut microbiota in nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37(4): 939-942. DOI: 10.3969/j.issn.1001-5256.2021.04.046. 刘巧红, 赵瑜, 胡义扬. 饮食对非酒精性脂肪性肝病肠道微生物菌型相关菌群的影响[J]. 临床肝胆病杂志, 2021, 37(4): 939-942. DOI: 10.3969/j.issn.1001-5256.2021.04.046.
[2]	ESTES C, RAZAVI H, LOOMBA R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology, 2018, 67(1): 123-133. DOI: 10.1002/hep.29466.
[3]	BUZZETTI E, PINZANI M, TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048. DOI: 10.1016/j.metabol.2015.12.012.
[4]	HOUTTU V, BOULUND U, GREFHORST A, et al. The role of the gut microbiome and exercise in non-alcoholic fatty liver disease[J]. Therap Adv Gastroenterol, 2020, 13: 1756284820941745. DOI: 10.1177/1756284820941745.
[5]	SHAN R, CHEN Y, YAO Z. Advance in research on the relationship between intestinal flora and non-alcoholic fatty liver disease[J]. Chin J Microecol, 2019, 31(7): 841-843. DOI: 10.13381/j.cnki.cjm.201907021. 单蕊, 陈燕, 姚政. 肠道菌群与非酒精性脂肪肝病相关性研究进展[J]. 中国微生态学杂志, 2019, 31(7): 841-843. DOI: 10.13381/j.cnki.cjm.201907021.
[6]	MOUZAKI M, COMELLI EM, ARENDT BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2013, 58(1): 120-127. DOI: 10.1002/hep.26319.
[7]	WONG VW, TSE CH, LAM TT, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis-a longitudinal study[J]. PLoS One, 2013, 8(4): e62885. DOI: 10.1371/journal.pone.0062885.
[8]	BASTIAN WP, HASAN I, LESMANA C, et al. Gut microbiota profiles in nonalcoholic fatty liver disease and its possible impact on disease progression evaluated with transient elastography: Lesson learnt from 60 cases[J]. Case Rep Gastroenterol, 2019, 13(1): 125-133. DOI: 10.1159/000498946.
[9]	SOBHONSLIDSUK A, CHANPRASERTYOTHIN S, PONGRUJIKORN T, et al. The association of gut microbiota with nonalcoholic steatohepatitis in Thais[J]. Biomed Res Int, 2018, 2018: 9340316. DOI: 10.1155/2018/9340316.
[10]	ZHU L, BAKER SS, GILL C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH[J]. Hepatology, 2013, 57(2): 601-609. DOI: 10.1002/hep.26093.
[11]	LOOMBA R, SEGURITAN V, LI W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease[J]. Cell Metab, 2017, 25(5): 1054-1062.e5. DOI: 10.1016/j.cmet.2019.08.002.
[12]	ADOLPH TE, GRANDER C, MOSCHEN AR, et al. Liver-microbiome axis in health and disease[J]. Trends Immunol, 2018, 39(9): 712-723. DOI: 10.1016/j.it.2018.05.002.
[13]	QIAO B, ZHOU Y, MA WJ, et al. Intestinal microflora imbalance in non-alcoholic fatty liver disease[J/CD]. Chin J Liver Dis (Electronic Version), 2020, 12(4): 29-33. DOI: 10.3969/j.issn.1674-7380.2020.04.005. 乔兵, 周永, 马文洁, 等. 肠道菌群失调在非酒精性脂肪性肝病中研究进展[J/CD]. 中国肝脏病杂志(电子版), 2020, 12(4): 29-33. DOI: 10.3969/j.issn.1674-7380.2020.04.005.
[14]	OTHMAN M, AGVERO R, LIN HC. Alterations in intestinal microbial flora and human disease[J]. Curr Opin Gastroenterol, 2008, 24(1): 11-16. DOI: 10.1097/MOG.0b013e3282f2b0d7.
[15]	RITZE Y, BÁRDOS G, HUBERT A, et al. Effect of tryptophan supplementation on diet-induced non-alcoholic fatty liver disease in mice[J]. Br J Nutr, 2014, 112(1): 1-7. DOI: 10.1017/S0007114514000440.
[16]	ZHANG X, COKER OO, CHU ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites[J]. Gut, 2021, 70(4): 761-774. DOI: 10.1136/gutjnl-2019-319664.
[17]	CHEN WJ, FU Y, WANG ZL. The effect of berberine combined with escitalopram in the treatment of sleep disturbance in senile depression and its effect on serum serotonin level[J]. Chin J Gerontol, 2020, 40(13): 2827-2829. DOI: 10.3969/j.issn.1005-9202.2020.13.046. 陈韦伽, 付裕, 王中莉. 小檗碱联合艾司西酞普兰治疗老年抑郁症睡眠障碍的效果及对血清5-羟色胺水平的影响[J]. 中国老年学杂志, 2020, 40(13): 2827-2829. DOI: 10.3969/j.issn.1005-9202.2020.13.046.
[18]	CHANG CM, HSIEH MS, YANG TC, et al. Selective serotonin reuptake inhibitors and the risk of hepatocellular carcinoma in hepatitis B virus-infected patients[J]. Cancer Manag Res, 2017, 9: 709-720. DOI: 10.2147/CMAR.S148097.
[19]	MA L, LI H, HU J, et al. Indole alleviates diet-induced hepatic steatosis and inflammation in a manner involving myeloid cell 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3[J]. Hepatology, 2020, 72(4): 1191-1203. DOI: 10.1002/hep.31115.
[20]	ROAGER HM, LICHT TR. Microbial tryptophan catabolites in health and disease[J]. Nat Commun, 2018, 9(1): 3294. DOI: 10.1038/s41467-018-05470-4.
[21]	YOUNOSSI Z, TACKE F, ARRESE M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology, 2019, 69(6): 2672-2682. DOI: 10.1002/hep.30251.
[22]	SMITH T. A modification of the method for determining the production of indol by bacteria[J]. J Exp Med, 1897, 2(5): 543-547. DOI: 10.1084/jem.2.5.543.
[23]	YANO JM, YU K, DONALDSON GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis[J]. Cell, 2015, 161(2): 264-276. DOI: 10.1016/j.cell.2015.02.047.
[24]	LAURANS L, VENTECLEF N, HADDAD Y, et al. Genetic deficiency of indoleamine 2, 3-dioxygenase promotes gut microbiota-mediated metabolic health[J]. Nat Med, 2018, 24(8): 1113-1120. DOI: 10.1038/s41591-018-0060-4.
[25]	SAKURAI T, ODAMAKI T, XIAO JZ. Production of indole-3-lactic acid by bifidobacterium strains isolated fromhuman infants[J]. Microorganisms, 2019, 7(9): 340. DOI: 10.3390/microorganisms7090340.
[26]	LEE JH, LEE J. Indole as an intercellular signal in microbial communities[J]. FEMS Microbiol Rev, 2010, 34(4): 426-444. DOI: 10.1111/j.1574-6976.2009.00204.x.
[27]	CHEN H, FINK GR. Feedback control of morphogenesis in fungi by aromatic alcohols[J]. Genes Dev, 2006, 20(9): 1150-1161. DOI: 10.1101/gad.1411806.
[28]	TILG H, ZMORA N, ADOLPH TE, et al. The intestinal microbiota fuelling metabolic inflammation[J]. Nat Rev Immunol, 2020, 20(1): 40-54. DOI: 10.1038/s41577-019-0198-4.
[29]	ZELANTE T, IANNITTI RG, CUNHA C, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22[J]. Immunity, 2013, 39(2): 372-385. DOI: 10.1016/j.immuni.2013.08.003.
[30]	TAKAMURA T, HARAMA D, FUKUMOTO S, et al. Lactobacillus bulgaricus OLL1181 activates the aryl hydrocarbon receptor pathway and inhibits colitis[J]. Immunol Cell Biol, 2011, 89(7): 817-822. DOI: 10.1038/icb.2010.165.
[31]	CERVANTES-BARRAGAN L, CHAI JN, TIANERO MD, et al. Lactobacillus reuteri induces gut intraepithelial CD4⁺CD8αα⁺ T cells[J]. Science, 2017, 357(6353): 806-810. DOI: 10.1126/science.aah5825.
[32]	RAI RP, LIU Y, IYER SS, et al. Blocking integrin α4β7-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis[J]. J Hepatol, 2020, 73(5): 1013-1022. DOI: 10.1016/j.jhep.2020.05.047.
[33]	WILCK N, MATUS MG, KEARNEY SM, et al. Salt-responsive gut commensal modulates TH17 axis and disease[J]. Nature, 2017, 551(7682): 585-589. DOI: 10.1038/nature24628.
[34]	SHARPTON SR, SCHNABL B, KNIGHT R, et al. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease[J]. Cell Metab, 2021, 33(1): 21-32. DOI: 10.1016/j.cmet.2020.11.010.
[35]	SHAJIB MS, BARANOV A, KHAN WI. Diverse effects of gut-derived serotonin in intestinal inflammation[J]. ACS Chem Neurosci, 2017, 8(5): 920-931. DOI: 10.1021/acschemneuro.6b00414.
[36]	ZHANG J, ZHU S, MA N, et al. Metabolites of microbiota response to tryptophan and intestinal mucosal immunity: A therapeutic target to control intestinal inflammation[J]. Med Res Rev, 2021, 41(2): 1061-1088. DOI: 10.1002/med.21752.
[37]	WLODARSKA M, LUO C, KOLDE R, et al. Indoleacrylic acid produced by commensal peptostreptococcus species suppresses inflammation[J]. Cell Host Microbe, 2017, 22(1): 25-37. DOI: 10.1016/j.chom.2017.06.007.
[38]	HOU Q, YE L, LIU H, et al. Lactobacillus accelerates ISCs regeneration to protect the integrity of intestinal mucosa through activation of STAT3 signaling pathway induced by LPLs secretion of IL-22[J]. Cell Death Differ, 2018, 25(9): 1657-1670. DOI: 10.1038/s41418-018-0070-2.
[39]	NI Y, NI L, ZHUGE F, et al. The gut microbiota and its metabolites, novel targets for treating and preventing non-alcoholic fatty liver disease[J]. Mol Nutr Food Res, 2020, 64(17): e2000375. DOI: 10.1002/mnfr.202000375.
[40]	BANSAL T, ALANIZ RC, WOOD TK, et al. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation[J]. Proc Natl Acad Sci U S A, 2010, 107(1): 228-233. DOI: 10.1073/pnas.0906112107.
[41]	SMITH BK, MARCINKO K, DESJARDINS EM, et al. Treatment of nonalcoholic fatty liver disease: role of AMPK[J]. Am J Physiol Endocrinol Metab, 2016, 311(4): e730-e740. DOI: 10.1152/ajpendo.00225.2016.
[42]	de MELLO VD, PAANANEN J, LINDSTRÖM J, et al. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study[J]. Sci Rep, 2017, 7: 46337. DOI: 10.1038/srep46337.
[43]	TARANTINO G, BALSANO C. Gastrointestinal peptides and nonalcoholic fatty liver disease[J]. Curr Opin Endocrinol Diabetes Obes, 2020, 27(1): 11-15. DOI: 10.1097/MED.0000000000000514.
[44]	MACIA L, TAN J, VIEIRA AT, et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome[J]. Nat Commun, 2015, 6: 6734. DOI: 10.1038/ncomms7734.
[45]	BLASLOV K, BULUM T, ZIBAR K, et al. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(23): 7356-7365. DOI: 10.3748/wjg.v20.i23.7356.
[46]	VOIGT JP, FINK H. Serotonin controlling feeding and satiety[J]. Behav Brain Res, 2015, 277: 14-31. DOI: 10.1016/j.bbr.2014.08.065.
[47]	ARON-WISNEWSKY J, WARMBRUNN MV, NIEUWDORP M, et al. Metabolism and metabolic disorders and the microbiome: The intestinal microbiota associated with obesity, lipid metabolism, and metabolic health-pathophysiology and therapeutic strategies[J]. Gastroenterology, 2021, 160(2): 573-599. DOI: 10.1053/j.gastro.2020.10.057.
[48]	HWANG SB, LEE BH. Anti-obesity and antidiabetic effects of nelumbinis semen powder in high-fat diet-induced obese C57BL/6 mice[J]. Nutrients, 2020, 12(11): 3576. DOI: 10.3390/nu12113576.
[49]	SCHWENGER K, BOLZON CM, LI C, et al. Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria[J]. Eur J Nutr, 2019, 58(5): 1771-1784. DOI: 10.1007/s00394-018-1844-5.
[50]	BEAUMONT M, NEYRINCK AM, OLIVARES M, et al. The gut microbiota metabolite indole alleviates liver inflammation in mice[J]. FASEB J, 2018, 32(12): fj201800544. DOI: 10.1096/fj.201800544.
[51]	JI Y, GAO Y, CHEN H, et al. Indole-3-acetic acid alleviates nonalcoholic fatty liver disease in mice via attenuation of hepatic lipogenesis, and oxidative and inflammatory stress[J]. Nutrients, 2019, 11(9): 2062. DOI: 10.3390/nu11092062.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1)

Get Citation

PDF

XML

Article Metrics

Article views (1023) PDF downloads(89)

Role of gut microbiota and tryptophan metabolism in nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.06.040

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of gut microbiota and tryptophan metabolism in nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.06.040

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content